Arkema SA (OTCMKTS:ARKAY) Given Consensus Rating of “Reduce” by Analysts

Arkema SA (OTCMKTS:ARKAY) has been given an average recommendation of “Reduce” by the eight brokerages that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating on the company.

Several research firms recently commented on ARKAY. Kepler Capital Markets lowered shares of Arkema from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. Zacks Research lowered shares of Arkema from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 6th. The Goldman Sachs Group raised Arkema from a “hold” rating to a “buy” rating in a research report on Tuesday, February 10th. Finally, Deutsche Bank Aktiengesellschaft downgraded Arkema from a “buy” rating to a “hold” rating in a research note on Monday, November 24th.

Arkema Stock Down 4.5%

OTCMKTS:ARKAY opened at $59.02 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.07 and a quick ratio of 2.26. The firm’s 50-day moving average price is $65.70 and its 200-day moving average price is $63.18. The company has a market capitalization of $4.49 billion, a PE ratio of 67.84, a P/E/G ratio of 1.52 and a beta of 0.87. Arkema has a 1-year low of $56.28 and a 1-year high of $84.62.

About Arkema

Arkema SA is a global specialty chemicals and advanced materials company headquartered in Colombes, France. Established in 2004 as a spin-off from Total’s chemicals division, the company offers a broad portfolio of high-performance materials designed to improve durability, thermal and chemical resistance, and environmental performance across diverse industries.

Arkema’s operations are organized into four core segments. Adhesive Solutions delivers bonding, sealing, and coating technologies for markets such as packaging, medical devices, and consumer goods.